Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615000366550
Ethics application status
Approved
Date submitted
22/01/2015
Date registered
22/04/2015
Date last updated
9/08/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Laser therapy in pressure ulcers: healing mechanisms
Scientific title
Effect of laser irradiation at different wavelengths (940, 808, and 658 nm) on healing mechanisms in human pressure ulcers
Secondary ID [1] 286034 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pressure ulcers 294005 0
Chronic wound healing 294006 0
Condition category
Condition code
Physical Medicine / Rehabilitation 294305 294305 0 0
Other physical medicine / rehabilitation
Skin 294306 294306 0 0
Other skin conditions
Inflammatory and Immune System 294307 294307 0 0
Normal development and function of the immune system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The aim of this clinical research will be to assess the effect of laser irradiation at different wavelengths (940, 808, and 658 nm) on the healing mechanisms in human pressure ulcers.

Intervention:
Patients with pressure ulcers from groups A, B and C will receive laser therapy once daily, 5 times per week for 1 month. The equipment will be a gallium-aluminum-arsenide (GaAlAs) diode laser with an output power of 50 mW and continuous radiation emission at separate wavelengths of 940 nm (group A), 808 nm (group B) and 658 nm (group C). The spot size will be 0.1 cm2. The laser will be wired to a cone-shaped applicator (scanner). The duration of a single procedure will be relative to the wound size; the therapy will be adjusted to obtain an average dose of 4 J/cm2 (direct dose measured on a surface of the wound). In group D, the placebo group, a laser will be applied in the same manner, but the device will be turned off during the treatment sessions (only the applicator will be turned on to scan ulcers using non-coherent red visible light).

Intervention code [1] 291017 0
Treatment: Devices
Comparator / control treatment
Single blind placebo (sham laser irradiation)
Control group
Placebo

Outcomes
Primary outcome [1] 294112 0
Immunocytochemical and pathological analysis of the biological material from the wound is to observe tissue parameter changes under the influence of laser stimulations.

Outcomes include:
1. Quantitative analysis of the factors influencing the angiogenesis processes, endothelial cell proliferation and cell death (apoptosis) and immunocytochemical analysis of microvasculature density, as an indicator of angiogenesis process.

Tools/tests used:
ELISA test, fluorescence microscope capillaroscopy
Timepoint [1] 294112 0
After one month therapy
Primary outcome [2] 294113 0
The overall objective of the in vitro testing is the analysis of biological activity of fibroblasts in primary bacterial culture, derived from the wounds, under the influence of laser stimulations.

Outcome include:
1. The assessment of viability and proliferative capacity of cells and apoptosis after laser stimulation with the analysis of the level of fibroblast growth factor and the degree of fibroblasts transformation into myofibroblasts.

Tools/tests used:
serum assay, TUNEL technique
Timepoint [2] 294113 0
After one month therapy
Primary outcome [3] 294114 0
The overall objective of the biochemical examination of blood serum and plasma is to observe a changes of the inflammatory response under the influence of laser stimulations.

Outcome include:
1. The assessment of inflammatory markers and coagulation factors which play an important role in the molecular mechanism of inflammatory and proliferation phase of the wound healing process.


Tools/tests used:
ELISA test
Timepoint [3] 294114 0
After one month therapy
Secondary outcome [1] 312523 0
The overall objective of bacteriological examination of biological material from the wound is the analysis of qualitative and quantitative changes in bacterial biofilm under the influence of laser stimulations.

Outcome include:
1. Qualitative analysis of bacterial wound biofilm, taking into account each of the bacteria strains having a direct impact on healing disturbances or increasing risk of inflammatory reactions with the analysis of possible bacteriostatic or antibacterial effect within the wound.

Tools/tests used:
serum assay, Gram technique, cytokine assay
Timepoint [1] 312523 0
After one month therapy

Eligibility
Key inclusion criteria
Participating subjects will meet the following inclusion criteria: (1) presented with a lower extremity pressure ulcer and (2) provided written informed consent to participate in the study. There will be no restrictions on gender, race, age, or ulcer duration.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Subjects with the following conditions will not be allowed to participate or will be excluded from the study: (1) clinically detectable infection in the ulcer (critical colonization of bacteria, no signs of healing for two weeks, friable granulation tissue, foul odor, increased pain in the ulcer, increased heat in the tissue around the ulcer, an ominous change in the nature of the wound drainage, e.g., new onset of bloody drainage or purulent drainage, or necrotic tissue in the ulcer); (2) use of drugs, such as corticosteroids, that could interfere with the wound-healing process; (3) use of special dressings, such as hydrocolloids, calcium alginate, activated carbon or any type of therapeutic procedure different from that used routinely by all groups in the study; (4) non-attendance to the therapeutic program; (5) pregnancy; (6) ankle-brachial pressure index (ABPI)<0.8; (7) diabetes mellitus; (8) systemic sclerosis; (9) cancer diagnosis; and (10) pareses and paralysis caused by injuries to the central or peripheral nervous system. Patients whose pressure ulcers required surgical intervention will also be excluded from the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be randomly allocated to the groups. Computer-generated random numbers will be sealed in sequentially numbered envelopes, and the group allocation be independent of the time and person delivering the treatment. The physician (research coordinator) who will allocate the subjects to groups have envelopes, each containing a piece of paper marked with either group A, B, C or D. The physician will select and open an envelope in the presence of a physiotherapist to see the symbol and then direct the patient to the corresponding group.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using computer and numbered envelopes
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Analysis and evaluation of the results will be based on the comparison of intra- and intergroup results. Statistical analysis of these results will be performed by means of the Statistica 10 software, manufactured by StatSoft (licence of Academy School of Physical Education). All analysed intergroup variables will be checked with respect to their similarity (uniformity; chi2 NW). A critical significance level a (alpha) = 0.05 or less will be considered statistically significant. For measurable variables (quantitative), arithmetic mean, standard deviations, medians and range of variability (extreme values) will be calculated. For qualitative variables, the frequency of occurrence (percentage) will be calculated. Comparison of intergroup results in order to determine the significance of the achieved differences, will be performed by means of parametric (ANOVA, Student's t-test, Welch's t test) or non-parametric (Mann-Whitney`s and Fischer tests, depending on meeting criteria for the specific test. Correlation of variables in the examined groups will also be checked.

To achieve study objectives the absolute minimal number of participants should be 15 in each group (for non-parametric tests). Smaller number of patients will not be enough from both statistical and clinical point of view (the smaller number of patients is not enough for reliable statistical analysis because of too large standard deviations due to characteristics of patients). However, the most reliable number od patients should be 30 in each comparative group (we will be able to use parametric tests). The reliable number of participants was estimated by Statistica 10 software, manufactured by StatSoft.

In calculating our sample size we have allowed for:
1. 30% loss of participants (exclusion criteria)
2. Historical information from our unit that 45% of patients who are offered conservative (standard physical therapy) management for this condition opt for laser therapy within 6 months.

This investigation has 95% power to detect a difference between group mean (SD) in the primary and secondary outcomes of 10 patients.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
27/04/2015
Actual
27/04/2015
Date of last participant enrolment
Anticipated
Actual
14/05/2018
Date of last data collection
Anticipated
Actual
11/06/2018
Sample size
Target
120
Accrual to date
Final
120
Recruitment outside Australia
Country [1] 6608 0
Poland
State/province [1] 6608 0

Funding & Sponsors
Funding source category [1] 290625 0
Charities/Societies/Foundations
Name [1] 290625 0
European Pressure Ulcer Advisory Panel (EPUAP)
Country [1] 290625 0
United Kingdom
Funding source category [2] 290952 0
Charities/Societies/Foundations
Name [2] 290952 0
Polish Society of Lymphology
Country [2] 290952 0
Poland
Primary sponsor type
Individual
Name
Prof. Jakub Taradaj
Address
Department of Physiotherapy Basics
Academy School of Physical Education
Mikolowska Street 72A 40-065 Katowice
Country
Poland
Secondary sponsor category [1] 289633 0
Individual
Name [1] 289633 0
Prof. Dimitri Beeckman
Address [1] 289633 0
University Centre for Nursing and Midwifery
Ghent University
De Pintelaan 185 5K3 B-9000 Ghent
Country [1] 289633 0
Belgium

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 292255 0
The Research Ethics Commitee from the Academy of Physical Education in Katowice, Poland
Ethics committee address [1] 292255 0
Ethics committee country [1] 292255 0
Poland
Date submitted for ethics approval [1] 292255 0
02/04/2014
Approval date [1] 292255 0
15/05/2014
Ethics approval number [1] 292255 0
4/2014

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 54334 0
Prof Jakub Taradaj
Address 54334 0
Department of Physiotherapy Basics, Academy School of Physical Education, Mikolowska 72 Street 40-065 Katowice
Country 54334 0
Poland
Phone 54334 0
+48668613945
Fax 54334 0
Email 54334 0
[email protected]
Contact person for public queries
Name 54335 0
Jakub Taradaj
Address 54335 0
Department of Physiotherapy Basics, Academy School of Physical Education, Mikolowska 72 Street 40-065 Katowice
Country 54335 0
Poland
Phone 54335 0
+48668613945
Fax 54335 0
Email 54335 0
[email protected]
Contact person for scientific queries
Name 54336 0
Jakub Taradaj
Address 54336 0
Department of Physiotherapy Basics, Academy School of Physical Education, Mikolowska 72 Street 40-065 Katowice
Country 54336 0
Poland
Phone 54336 0
+48668613945
Fax 54336 0
Email 54336 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseEffect of laser therapy on expression of angio-and fibrogenic factors, and cytokine concentrations during the healing process of human pressure ulcers.2018https://dx.doi.org/10.7150/ijms.25651
N.B. These documents automatically identified may not have been verified by the study sponsor.